We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rare Genetic Variants Can Contribute to Ischemic Heart Failure

By LabMedica International staff writers
Posted on 29 Dec 2020
Print article
Image: Illustration of Normal Heart versus Heart with Dilated Cardiomyopathy (Photo courtesy of Medical gallery of Blausen Medical).
Image: Illustration of Normal Heart versus Heart with Dilated Cardiomyopathy (Photo courtesy of Medical gallery of Blausen Medical).
Heart failure affects about 40 million people globally, and most cases are due to ischemic heart disease, hypertension, or cardiomyopathies. Cardiomyopathies have been traced to rare variants in genes that encode sarcomere or cytoskeletal proteins, channels, or desmosomes, while genome-wide association studies have underscored common variants linked to heart failure.

Mendelian genetic conditions may represent an important subset of complex late-onset diseases such as heart failure, irrespective of the clinical presentation. Sequencing studies have identified causal genetic variants for distinct subtypes of heart failure (HF) such as hypertrophic or dilated cardiomyopathy. However, the role of rare, high-impact variants in HF, for which ischemic heart disease is the leading cause, has not been systematically investigated.

Medical scientists at the Columbia University Medical Center (New York, NY, USA) and their international colleagues sequenced the exomes of 5,942 people with heart failure from the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) and the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) clinical trials. The mean age (± SD) was 68.9 ± 9.9 years and 4,213 (70.9%) were male. Most of the patients in the CORONA and CHARM trial had heart failure with reduced ejection fraction, though a portion of the CHARM study patients had heart failure with preserved ejection fraction. The studies included 13,156 unrelated controls.

The team reported that in their analysis of all heart failure subtypes, the TTN gene reached study wide significance, with the strongest association in a dominant protein truncation variant model. Protein truncation variants in TTN are a known cause of cardiomyopathy, particularly dilated cardiomyopathy. Most of the cardiomyopathy-associated variants cluster in the distal exons, and the likelihood that a variant is pathogenic can be captured by the proportion spliced-in (PSI) metric. More than 55% of heart failure patients with TTN-truncating variants with high PSI scores had ischemic heart disease as their primary etiology, suggesting that even though TTN variants are only known to cause nonischemic cardiomyopathies, they are enriched among heart failure patients with ischemic disease, as compared to controls.

The team also noted that the TET2 gene reached significance in a protein truncation variant model among the subgroup with heart failure with reduced ejection fraction from the CORONA trial. In a diagnostic analysis of 41 known cardiomyopathy genes, they uncovered 204 diagnostic variants in 201 of 5,916 heart failure patients. Large portions (61.3%) of the diagnostic variants were TTN-truncating variants. Among people with ischemic heart disease, they uncovered diagnostic variants in a number of dilated cardiomyopathy genes like TTN, DSG2, and BAG3.

The authors concluded that an increased burden of diagnostic Mendelian cardiomyopathy variants in a broad group of patients with HF of mostly ischemic etiology compared with controls was observed. This work provides further evidence that Mendelian genetic conditions may represent an important subset of complex late-onset diseases such as HF, irrespective of the clinical presentation. The study was published on December 16, 2020 in the journal JAMA Cardiology.

Related Links:
Columbia University Medical Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.